Exicure, Inc. (XCUR): Operating Cash Flow
-$8.55M
Year ended 2025-12-31
-$6.70M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$8.55M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$2.91M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$10.36M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$35.66M | n/m | 2024-06-06, From 2022-01-01 |
| 2021-12-31 | -$34.82M | n/m | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | -$39.27M | n/m | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $1.32M | n/m | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | -$19.49M | n/m | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | -$19.79M | n/m | 2019-09-23, From 2017-01-01 |
| 2016-12-31 | -$5.05M | n/a | 2018-03-09, From 2016-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 2025-12-31 | -$8.55M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
Compare XCUR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗